scholarly journals Hepatitis B Envelope Antigen in Children and Adults with Hepatitis B Infection in Tertiary Health Facility in North East Nigeria During the Period 2000-2015

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Isaac WE ◽  
◽  
Jalo I ◽  
Ajani A ◽  
Oyeniyi CO ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Age Group ◽  
Middle Income ◽  
North East ◽  
Positive Hbsag ◽  
Group 5 ◽  
Envelope Antigen

Introduction: Worldwide, most people living with chronic HBV infection are in in low- and middle-income countries. Most of the burden of disease from HBV infection comes from infections acquired before the age of 5 years. Materials and Methods: Records of Hepatitis B surface and envelope antigen results of children and adults in Federal Teaching Hospital, Gombe between May 2000 and May 2015 were analyzed Results: 22,862 individuals were tested for Hepatitis B surface antigen. 19.5% (4456) tested positive. 24.7 % (3146) and 12.9% (1310) of males and females respectively were HBsAg positive. HBsAg Peak prevalence of 21.8% was in the age group 26-46 (2533) and the lowest prevalence in infancy (3.5%). Amongst males, the 19-25year age group had the peak prevalence of 28.6% and in females the age group 5-9 years constituted the highest (20.3%). 36% (1602/4456) of HBsAg positive children and adults were tested for HBeAg. 26.2% (420/1602) of individuals with HBsAg carriage were HBeAg. More males (307/1105) than females (113/495) were HBeAg positive but not statistically significant. (P=0.034). Prevalence of HBeAg was highest in infants (50%) and children 1-4 years (50%) age group and thereafter declined with increasing age. Females of the younger age group <1year, 1-4 years and 5-9 years and older age group, 56-65 and >65 years, compared to their male carriers of HBsAg had higher prevalence of HBeAg but these were not statistically significant. Conclusion: A fifth of HBsAg carriers were HBeAg positive and HBeAg positivity decreased with increasing age. Hepatitis B vaccination in Nigeria requires urgent strengthening. Keywords: Hepatitis, HBsAg, HBeAg Children, Adults, Nigeria.

scholarly journals 1066. Immune Escape Mutant Detection Using Commercially Available Methods for Hepatitis B Surface Antigen Serological Testing

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S562-S562
Author(s):  
Robert Gish ◽  
Vincent Streva
Keyword(s):  
Hepatitis B ◽  
Immune Escape ◽  
Hepatitis B Surface Antigen ◽  
Panel Member ◽  
The United States ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Review Panel ◽  
B Virus ◽  
Escape Mutants

Abstract Background Although overall infection rates of Hepatitis B virus (HBV) in the United States (US) remain stable, as many as 2.2 million persons are still chronically infected with Hepatitis B Virus (HBV)1. Persons who inject drugs (PWID) are at a higher risk of HBV infection and since 2009 three states (KY, TN, WV) have reported up to a 114% increase in cases of acute HBV infection due to higher infection rates among a non-Hispanic white populations (30–39 years), and injection drug users2. Hepatitis B vaccination is recommended as primary prevention for adults who are at increased risk for HBV infection, including PWID. However, data from the National Health Interview Survey indicate that hepatitis B vaccination coverage is low among adults in the general population3, and it is likely to be lower among injection drug users. Hepatitis B Surface Antigen (HBsAg) is the first serological marker to appear after HBV exposure and infection; this marker is included in the recommended panel for acute hepatitis diagnosis and accurate detection is necessary for early and accurate diagnosis. Serological testing challenges exist for HBsAg due to the high degree of genetic variability which can further be exacerbated by endogenous and exogenous pressures. The immuno-dominant region may have one or more mutations described as immune escape mutations which can decrease or abrogate HBsAg binding to antibodies used in immunoassays. Although the prevalence of these mutations is not well documented in the United States, international studies have shown that up to 79% of HBV-reactivated patients (vs 3.1% of control patients; p&lt; 0.001) carry HBsAg mutations localized in immune-active HBsAg regions4. Methods A study was conducted using a panel of 10 unique recombinant HBsAg immune escape mutants. Panel members were tested by commercially available HBsAg serological immunoassays. Results It was found that although commercially available HBsAg immunoassays are the primary diagnostic tool for HBV diagnosis, not all HBsAg immune escape mutants are detected, with some method detecting as few as 5 out of 10 of these mutant samples. Figure 1 Conclusion Improvement is needed in commercially available methods for the accurate detection of HBsAg. Disclosures Robert Gish, MD, Abbott (Consultant)AbbVie (Consultant, Advisor or Review Panel member, Speaker’s Bureau)Access Biologicals (Consultant)Antios (Consultant)Arrowhead (Consultant)Bayer (Consultant, Speaker’s Bureau)Bristol Myers (Consultant, Speaker’s Bureau)Dova (Consultant, Speaker’s Bureau)Dynavax (Consultant)Eiger (Consultant, Advisor or Review Panel member)Eisai (Consultant, Speaker’s Bureau)Enyo (Consultant)eStudySite (Consultant, Advisor or Review Panel member)Exelixis (Consultant)Fujifilm/Wako (Consultant)Genentech (Consultant)Genlantis (Consultant)Gilead (Consultant, Advisor or Review Panel member, Speaker’s Bureau)GLG (Consultant)HepaTX (Consultant, Advisor or Review Panel member)HepQuant (Consultant, Advisor or Review Panel member)Intercept (Consultant, Speaker’s Bureau)Ionis (Consultant)Janssen (Consultant)Laboratory for Advanced Medicine (Consultant)Lilly (Consultant)Merck (Consultant)Salix (Consultant, Speaker’s Bureau)Shionogi (Consultant, Speaker’s Bureau)Viking (Consultant)

scholarly journals Age-wise and Gender-wise Prevalence of Hepatitis B Virus (HBV) Infection in Lahore, Pakistan

2019 ◽  
Vol 01 (04) ◽  
pp. 20-28
Author(s):  
Aqib Nazeer ◽  
Shahid Ali ◽  
Imran Tipu
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Hbv Infection ◽  
Age Group ◽  
Pakistani Population ◽  
Blood Samples ◽  
Significant Difference ◽  
B Virus ◽  
And Gender

Background The prevalence of hepatitis B virus (HBV) in the Pakistani population has been reported previously, however, studies with a city-oriented approach and focus on age and gender distribution are very limited. Therefore, the current study was designed to unravel the age-wise and gender wise prevalence of HBV in Lahore, Pakistan. Methods A total of 350 blood samples of both male and female patients who visited National Genetic Laboratory, Lahore between February 2019 and July 2019 and who were suspected of HBV infection were screened. Sandwich based ELISA was used to detect rapid hepatitis B surface antigen (HbsAg) according to the manufacturer’s instruction. Real time PCR was used to detect HBV using HBV Rotor Gene PCR kit. Results Out of 350 blood samples screened for HBV infection (n= 350), 180 (51.43%) were of males and 170 (48.57%) were of females. Mean age (years) with SD (standard deviation) of the screened population was 37.22 ± 12.16 years. Overall, 224 samples (64%) were found to be positive for HBV infection. In our study, the number of females with this infection (52.24%) was slightly higher than males (47.76%). However, we observed no statistically significant difference (p = 0.225) between them. Conclusion Our study concludes that HBV is highly prevalent in Lahore, Pakistan. Females are slightly more susceptible to HBV infection as compared to males. This study also reports that HBV is more prevalent in the 20-40 age group.

scholarly journals Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation

2000 ◽  
Vol 14 (suppl b) ◽  
pp. 59B-63B ◽  
Author(s):  
Edith Villeneuve ◽  
Jean Vincelette ◽  
Jean-Pierre Villeneuve
Keyword(s):  
Liver Transplantation ◽  
Hepatitis B ◽  
De Novo ◽  
Hepatitis B Surface Antigen ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Hbv Vaccine ◽  
Hbv Vaccination ◽  
De Novo Hepatitis B ◽  
Cirrhotic Patients

Cirrhotic patients who undergo liver transplantation are at risk of acquiring de novo hepatitis B virus (HBV) infection at the time of transplantation. It is common practice to immunize these patients against HBV, but the efficacy of vaccination is uncertain. The response to vaccination with a recombinant HBV vaccine was examined in 49 patients with cirrhosis before liver transplantation. Patients received three doses (20 µg) of Engerix-B (SmithKline Beecham) at zero, one and two months before transplantation, and their response was measured on the day of liver transplantation (9.3±1.2 months after the initial dose of vaccine). Results were compared with those reported in healthy adults vaccinated according to the same schedule. Fourteen of 49 cirrhotic patients (28%) developed antibodies to hepatitis B surface antigen (anti-HBs) levels of more than 10 U/L after vaccination compared with 97% of healthy controls. Four patients (8%) had anti-HBs levels of more than 100 U/L compared with 83% in healthy individuals. Mean anti-HBs titre in the 14 responders was 62 U/L compared with 348 U/L in controls. No factor was identified that predicted response to vaccination. One of 49 patients acquired de novo HBV infection at the time of liver transplantation. Current HBV vaccination of cirrhotic patients waiting for liver transplantation is ineffective, and new strategies need to be developed to increase the response rate.

Hepatitis B Surface Antigen level and its Correlation with Age, Gender, and Liver Biomarkers

2021 ◽  
pp. 4207-4211
Author(s):  
Zainab A. Hamid ◽  
M. Sc Yasmeen J. Al-Bayaa ◽  
Ali Hattem Hussain
Keyword(s):  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Correlation Coefficients ◽  
Total Serum ◽  
Age Group ◽  
Patients Âgés ◽  
Positive Hbsag ◽  
Chronic Hbv ◽  
The Mean

Background: Measuring the concentration of hepatitis B surface antigen (HbsAg) in HBV patients can be determined with immunoassay techniques. This study aimed to measure the HbsAg titers in chronic HBV patients and to assess its correlation with patients' ages, gender, and with the levels of liver enzymes and total serum bilirubin. Materials and Method: Fifty-eight chronic hepatitis B infected patients were enrolled in this study. Age and gender of the patients were recorded. HbsAg concentration was tested with automated Immunoanalyzer. The patients were also tested for ALT, AST, ALP, and TSB by automated chemistry analyzer. Results: All the chronic HBV patients have positive HBsAg titers above the negative cutoff (0.05U/L) with mean concentration equal to 3099.7U/L, and a range of 0.25-6005.2 U/L. The highest mean HbsAg concentration was in age group 50-59, while the least was in age group ≥60. There was weak negative insignificant correlation between HbsAg concentrations and ages of patients. Thirty one of the patients were males and 27 were females. The means of HbsAg concentrations between males and females were statistically not significant. The mean ALT concentration was 60.038U/L, for AST was 40.728U/L, for ALP was 113.722 U/L, and for TSB was 1.168mg/dl. The values of correlation coefficients (R) between HBsAg titers and the concentrations of ALT, AST, ALP, and TSB were 0.13, 0.11, 0.12, and 0.14, respectively. Conclusions: The HBsAg titers are positive among all chronic HBV patients, with a mean titer of 3099.7U/L and all of the values are below 10000.0U/L. The mean titers increase gradually with age to reach the peak in age group 50-59 years old then decline The age, gender, serum ALT, serum AST, serum ALP, and TSB all have weak insignificant correlations with HBsAg titers among chronic HBV patients. The serum ALT is the most commonly elevated liver biomarker in chronic HBV patients.

STUDY OF PREVALENCE OF HEPATITIS B SURFACE ANTIGEN (HBSAG) IN BLOOD DONOR POPULATION BORN PRIOR TO AND AFTER IMPLEMENTATION OF HBV VACCINATION IN KERALA, SOUTH INDIA

2021 ◽  
pp. 66-67
Author(s):  
Indu . P.K
Keyword(s):  
Hepatitis B ◽  
Blood Donor ◽  
Blood Donors ◽  
Hepatitis B Surface Antigen ◽  
Vaccination Schedule ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
P Value ◽  
Hbv Vaccine ◽  
Hbv Vaccination

BACKGROUND: Since 1995 Hepatitis B vaccination became a part of Extended immunization Program (EIP) in India, neonates started getting immunoprophylaxis against Hepatitis B virus. Since vaccination started recently, exact prevalence of immunized persons were not available, but anyway vaccinated blood donors over 18 years old are progressively increasing MATERIALS AND METHODS: In this study 2400 blood donors were screened for HBsAg by enzyme linked immunosorbent assays, among the donor blood samples which are positive for HBsAg were noted. Various demographic patterns of blood donor were analyzed. To know about impact of vaccination on prevalence HBV infection among donors who born after the implementation of mandatory HBV vaccination schedule was compared with blood donors those who are born before HBV vaccination schedule RESULTS: Among the blood donors overall prevalence of HBV infection was 0.75% HBsAg. HBV vaccinated blood donor were protected from getting disease ,showing P value of 18 years (0.07), 19 years(0.01), 20 years(0.02) CONCLUSION: Young blood donors born after implementation of universal HBV vaccination in lndia presented higher prevalence of HBsAg but lower incidence of HBsAg seroconversion than older. HBV vaccine boosting for adolescents at 15–17 years old prior to reaching blood donor age may improve blood safety.

scholarly journals Hepatitis B seroprevalence in children and women and the impact of the hepatitis B vaccination program in the Black Sea Region of Turkey

2013 ◽  
Vol 7 (12) ◽  
pp. 960-965 ◽  
Author(s):  
Guner Karatekin ◽  
Mehmet Kilinc ◽  
Banu Gulcan Oksuz ◽  
Mahir Igde
Keyword(s):  
Hepatitis B ◽  
Black Sea ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Vaccination Program ◽  
Hepatitis B Vaccination ◽  
Age Group ◽  
Black Sea Region ◽  
Hbsag Seropositivity ◽  
The Impact

Introduction: This study aimed to determine the seroprevalence of hepatitis B virus (HBV) infection in children and females in the middle Black Sea Region of Turkey and to assess the impact of the universal infant hepatitis B vaccination program started in 1998. Methodology: The laboratory records of 12,057 patients who attended the Samsun Maternity and Children’s Hospital between January 2007 and November 2009 were evaluated retrospectively. In this period, hepatitis B surface antigen (HBsAg), the antibody to hepatitis B surface antigen (anti-HBs), was studied from serum samples using the enzyme linked immunosorbent assay method. Results: In the total population, HBsAg seropositivity was found to be 3.8% (456/12010); anti-HBs was 32.6% (3526/10800). HBsAg was 3.5%, in the 0-14 year age group, 8.2% in the 15-18 group, 3.3% in the 19-49 group, and 8.0% in the over 49 group. The seropositivity of HBsAg decreased by half in patients between zero and 14 years of age (4.2%) who were included in the universal vaccination program when compared with those in the 15-18 year group (8.2%) who were not included in the program. There was a significant difference in HBsAg seropositivity between boys (5.8%) and girls (3.9%) (p < 0.05). Conclusions: According to the hepatitis B seroprevalence records of our region, HBsAg was 3.5% in the 0-14 year age group, 8.2% in the 15-18 year group. It may therefore be suggested that, since 1998, the vaccination program in our region has been successful.

Hepatitis B Seroepidemiology in Australia, One Decade After Universal Vaccination of Infants and Adolescents

2020 ◽  
Vol 20 (3) ◽  
pp. 341-347
Author(s):  
Xinting Lu ◽  
Helen E. Quinn ◽  
Rob I. Menzies ◽  
Linda Hueston ◽  
Lyn Gilbert ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Age Groups ◽  
Baseline Period ◽  
Hbv Infection ◽  
Vaccine Uptake ◽  
Hepatitis B Vaccination ◽  
Vaccination Programs ◽  
Adolescent Vaccination ◽  
The Impact

Background: This study assessed the impact of the staged introduction of universal infant and adolescent catch-up hepatitis B vaccination programs on the prevalence of immunity and past hepatitis B virus (HBV) infection in targeted cohorts over almost a decade in Australia. Methods: We compared the prevalence of immunity in relevant cohorts of children and adolescents in repeated national serological surveys conducted in 1998-99, 2002 and 2007. Residual sera (n =2210) collected opportunistically from Australian laboratories in 2007 were tested for antibody to hepatitis B surface antigen (anti-HBs) indicating vaccine-induced immunity; sera from individuals aged 12-29 years with anti-HBs detected (n =386) were then tested for hepatitis B core antibody (anti-HBc) to identify past hepatitis B infection. Results: In 2007, compared with the baseline period of 1998-99, anti-HBs prevalence had increased significantly in all age groups below 24 years, by more than double in target children. Prevalence of anti-HBc was zero in the 12-14 years and reduced by 71% in those aged 15-19 years. The hepatitis B vaccination protected a significant number of targeted adolescents with a modest vaccine uptake (57% to 60% nationally). Conclusion: In a setting without incentives or school entry requirements, adolescent vaccination coverage was significantly higher when delivered by school-based rather than GP-based mechanisms. A cohort of children was growing up in Australia with a high prevalence of vaccineinduced immunity against hepatitis B, providing the best opportunity for controlling HBV infection in Australia.

scholarly journals Seroprevalence of Hepatitis B infection among pregnant women in South India

2016 ◽  
Vol 6 (1) ◽  
pp. 249 ◽  
Author(s):  
Sathiyakala Rajendiran ◽  
Ushadevi Gopalan ◽  
Karthika Jayakumar
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Pregnant Women ◽  
South India ◽  
Hepatitis B Surface Antigen ◽  
Hbv Infection ◽  
Age Group ◽  
Virus Hepatitis ◽  
Route Of Transmission ◽  
B Virus

Background: Vertical transmission of infection from mother to infants is a very important route of transmission of hepatitis B virus. Hepatitis B virus infection in pregnant women usually goes undetected. The hepatitis B surface antigen in serum is the first seromarker to indicate active HBV infection. This study was done to determine the seroprevalence of HBsAg in healthy asymptomatic antenatal women.Methods: It was a hospital based study over a period of two years. A total of 1282 antenatal patients were tested for hepatitis B surface antigen.Results: The prevalence rate of HBsAg was found to be 1.01 %( 13 positive out of 1282 cases). Highest prevalence was in age group 26-30(46%) followed by age group 31-35(30.8%) followed by age group 20-25 yrs (23.1%).Conclusions: Screening of all pregnant women for HBV irrespective of risk factors will reduce the prevalence and risks of HBV infection.

scholarly journals Trend of HBsAg Seroprevalence Among Blood Donors in a Nigerian Teaching Hospital: A Five-Year Retrospective Study

2021 ◽  
Vol 19 (2) ◽  
pp. 87-96
Author(s):  
Winifred Aitalegbe Ojieabu ◽  
◽  
Wasiu Adedeji Mukaila ◽  
Christabel Ebabhi Ojieabu ◽  
John Arute ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Teaching Hospital ◽  
Blood Donors ◽  
Hepatitis B Surface Antigen ◽  
Hbv Infection ◽  
University Teaching ◽  
World Health ◽  
Age Group ◽  
Hbsag Positivity ◽  
Ogun State

World Health Organization (WHO) classified Nigeria as a hyper-endemic hepatitis B surface antigen (HBsAg) positive nation with prevalence ≥ 8%. This study intends to add information that could strengthen established database to improve awareness and prevention of hepatitis B virus (HBV) infection. We aimed to evaluate seroprevalence and trend of HBsAg among blood donors in Olabisi Onabanjo University Teaching Hospital (OOUTH), Sagamu, Ogun State, Nigeria over a five-year period. Data from records of 7,102 individuals aged ≥ 20 years old who donated blood to blood bank in this hospital from January 2012 to December 2016 were analysed for gender, age, number of donors per year and HBsAg status. Data analysis was done with Statistical Package for Social Sciences software. P ≤ 0.05 was considered statistically significant. Males were in the majority (6,547 [92.2%]). Age 30–39 years old was the major group (3,052 [43.0%]). Pooled HBsAg seroprevalence was 486 (6.8%). Females had the highest HBsAg seroprevalence across board with highest rate of 10 (19.6%) in year 2012 and pooled prevalence of 73 (13.2%). Age group of ≥ 50 years old had highest HBsAg seroprevalence 39 (8.5%) while age group of 20–29 years old had least 128 (5.8%). Stratified HBsAg positivity decreased steadily from year 2012 to year 2016. This location was HBV intermediate-endemic. There were age, gender and yearly seroprevalence of HBsAg related trends which could be leveraged upon in finding effective preventive measures against the disease. We recommend mass vaccination by government against HBV infection in addition to provision of sensitive blood investigational equipment.

Sign in / Sign up

Export Citation Format

Share Document